ASSESSMENT OF THE EFFICACY OF BEVACIZUMAB IN COMBINATION WITH FOLFIRI AS SECOND-LINE TREATMENT IN PATIENTS SUFFERING FROM AN ADVANCED INOPERABLE POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF AN UNKNOWN OR GASTROENTERO-PANCREATIC PRIMARY CANCER: